Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 189

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A pilot study of atorvastatin treatment in dyslipemid, non‐alcoholic fatty liver patients

GÓMEZ‐DOMÍNGUEZ, E., GISBERT, J. P., MORENO‐MONTEAGUDO, J. A., GARCÍA‐BUEY, L., MORENO‐OTERO, R. · 2006 · Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: Non‐alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of liver injury. Currently, there are no proven effective therapies available. Atorvastatin is a new 3‐hydroxy‐3‐metylglutaryl coenzyme A reductase inhibitor that reduces lipid serum levels. Aim: To evaluate the effectiveness and safety of atorvastatin in dyslipemid, non‐alcoholic fatty liver patients. Patients and methods: We prospectively enrolled 25 patients with NAFLD; 22 of them completed the study. Body mass index, serum lipids, liver function tests and liver density assessed by echography were measured at baseline and after 1, 3, 6, 9 and 12 months of treatment. Normalization of transaminases and/or improvement in liver density were treatment end points. Patients received atorvastatin (10–80 mg/daily) according to basal serum choleresterol levels; additionally, they were given standard weight‐loss counselling and encouraged to follow a low fat diet. Results: All 22 patients (14 men, mean age 47 ± 10 years) had high cholesterol levels at baseline and 11 (44%) also presented high trygliceride levels. After 6 months of treatment, eight patients (36.3%) presented normal transaminase levels. The remaining patients continued treatment for 12 months when 20% of patients presented with normal transaminase levels, while the other patients showed a 10% reduction in basal levels. Mean cholesterol levels were 268.5 ± 44.2 and 186.8 ± 14.4 mg/dL before and after treatment, respectively (P < 0.05). The mean body mass index was 27.4 ± 3.1 at baseline and 26.3 ± 2.8 kg/cm 2 at the end of treatment (P > 0.05). No side effects were reported. Conclusions: Serum aminotransferase and lipid levels were reduced significantly in all patients with atorvastatin treatment. Therapy with atorvastatin in NAFLD patients with hyperlipidemia was found to be both effective and safe.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2006.02926.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 189

Metadata

Authors
GÓMEZ‐DOMÍNGUEZ, E., GISBERT, J. P., MORENO‐MONTEAGUDO, J. A., GARCÍA‐BUEY, L., & MORENO‐OTERO, R.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2006-05-12
Volume
23
Issue
11
Pages
1643-1647
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2009922326
Cited by
189
References
3
FWCI
10.62
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A pilot study of atorvastatin treatment in dyslipemid, non‐alcoholic fatty liver patients. https://app.cochat.ai/papers/10.1111/j.1365-2036.2006.02926.x
The paper
GÓMEZ‐DOMÍNGUEZ, E., GISBERT, J. P., MORENO‐MONTEAGUDO, J. A., GARCÍA‐BUEY, L., & MORENO‐OTERO, R. (2006). A pilot study of atorvastatin treatment in dyslipemid, non‐alcoholic fatty liver patients. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2006.02926.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.